Journal
JCO ONCOLOGY PRACTICE
Volume 18, Issue 3, Pages 187-+Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/OP.21.00419
Keywords
-
Categories
Ask authors/readers for more resources
Renal cell carcinomas show significant variations in tumor biology and disease progression, resulting in diverse treatment paradigms. Combination therapies have become the standard of care for most patients with metastatic renal cell carcinoma. This review highlights recent crucial data that have led to changes in treatment approaches and provides a practical framework for managing patients with mRCC.
Renal cell carcinomas vary considerably in their tumor biology and disease course, which is reflected in the range of treatment paradigms in localized and metastatic renal cell carcinoma (mRCC). Active surveillance remains an important component of all renal cell carcinoma management. In mRCC, the rapid evolution from cytokine-based therapy to targeted therapy to immunotherapy with checkpoint blockade has revolutionized the field and drastically altered treatment outcomes. More recently, combination therapies have become a standard of care for most patients with mRCC. In this review, we highlight recent critical data that led to changes in treatment paradigms and provide a practical framework for the management of patients with mRCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available